Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00156429 · ClinicalTrials.gov registry record
Genetic Predictors of Outcome in HCM Patients
A clinical trial, sponsored by University of Pittsburgh.
- Terminated
- Registry status
- 98
- Enrollment target
NCT00156429: Clinical Trial study, sponsored by University of Pittsburgh.
NCT00156429 is a clinical trial that was terminated before completion, run by University of Pittsburgh. The registered enrollment target is 98 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00156429 was terminated before completion, sponsored by University of Pittsburgh.
- TERMINATED
- Registry status
- 98 participants
- Enrollment target
Study Summary
This is a retrospective review of the data available on patients and their family members with HCM and prospective follow-up of this cohort for clinical outcome and diagnostic studies. Genetic samples are being examined in this cohort to determine whether certain to determine whether certain beta-AR polymorphisms as well as other common genetic polymorphisms are associated with different morphological features, such as LVH in patients with HCM and whether these polymorphisms influence the clinical course and outcome in patients with HCM. For that purpose, we will build a database with clinical information including serial echocardiographic measurements for patients with HCM that have regular follow up and test them for beta-AR polymorphisms as well as other common genetic polymorphisms and other known cardiac-related polymorphisms that can potentially contribute to the morphologic differences seen in patients with HCM.
Primary Outcome
AR polymorphisms will be correlated to progression of LVH and clinical outcome in patients with HCM.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2009-04-22 |
| Est. Completion | 2020-07-30 |
Why NCT00156429 stopped before completion
NCT00156429 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 98 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00156429 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00156429 about?
NCT00156429 is a clinical study titled "Genetic Predictors of Outcome in HCM Patients". This is a retrospective review of the data available on patients and their family members with HCM and prospective follow-up of this cohort for clinical outcome and diagnostic studies. Genetic samples are being examined in this cohort to determine whether certain to determine whether certain beta-AR...
What is the current status of trial NCT00156429?
This trial is currently terminated. The enrollment target is 98 participants. The study started on 2009-04-22. Estimated completion is 2020-07-30.
Who is sponsoring clinical trial NCT00156429?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI